Myriad Genetics Inc. Director Resigns — Dr. Daniel M. Skovronsky

What Happened
Myriad Genetics, Inc. (MYGN) filed an 8‑K (Item 5.02) on June 23, 2026 announcing that board member Daniel M. Skovronsky, M.D., Ph.D., notified the company of his immediate resignation effective June 17, 2026. The filing states his resignation was not the result of any disagreement with the company or any matter relating to its operations, policies, or practices.

Key Details

• Filing: Form 8‑K dated June 23, 2026 (Item 5.02).
• Effective date of resignation: June 17, 2026.
• Director: Daniel M. Skovronsky, M.D., Ph.D.
• Company statement: Resignation “was not a result of any disagreement with the Company or due to any matter relating to the Company’s operations, policies, or practices.”
• No replacement or additional departures were disclosed in this filing.

Why It Matters
Board changes affect corporate governance and investor oversight. This filing confirms a director left the board and that the departure was not due to disagreements with management or company practices. Investors should watch for future filings or press releases that disclose any appointment to fill the vacancy or changes to board committees.